TY - JOUR
T1 - Thyroid Monitoring After Intravascular Iodinated Contrast Media in Infants and Children Through 3 Years of Age
AU - Miller, Ryan S.
AU - Dillman, Jonathan R.
AU - Crystal, Matthew A.
AU - Bethin, Kathleen
AU - Dinauer, Catherine A.
AU - Forbes-Amrein, Monica
AU - Gordon, Brent M.
AU - Hughes, Bridget
AU - Lahoti, Amit
AU - Marshall, Audrey C.
AU - Mastrandrea, Lucy D.
AU - Pesce, Liuska M.
AU - Rapaport, Robert
AU - Salavitabar, Arash
AU - Wasserman, Jonathan D.
AU - Bauer, Andrew J.
AU - Wassner, Ari J.
N1 - Publisher Copyright:
Copyright © 2026 by the American Academy of Pediatrics
PY - 2026/5
Y1 - 2026/5
N2 - In March 2022, the US Food and Drug Administration issued a drug safety communication (DSC) recommending monitoring of thyroid function in children up to 3 years of age who receive intravascular injection of iodinated contrast media (IV ICM) for medical imaging. In response, a group of pediatric and imaging experts convened to review the current scientific evidence on thyroid dysfunction after IV ICM and to provide recommendations on thyroid testing and management after IV ICM administration in infants and children. There are considerable gaps in knowledge related to the risk of thyroid dysfunction in young children exposed to IV ICM, and we strongly recommend that high-quality prospective studies be proposed and funded to clarify the incidence, risk modifiers, natural history, and outcomes of thyroid dysfunction after IV ICM exposure in this population.
AB - In March 2022, the US Food and Drug Administration issued a drug safety communication (DSC) recommending monitoring of thyroid function in children up to 3 years of age who receive intravascular injection of iodinated contrast media (IV ICM) for medical imaging. In response, a group of pediatric and imaging experts convened to review the current scientific evidence on thyroid dysfunction after IV ICM and to provide recommendations on thyroid testing and management after IV ICM administration in infants and children. There are considerable gaps in knowledge related to the risk of thyroid dysfunction in young children exposed to IV ICM, and we strongly recommend that high-quality prospective studies be proposed and funded to clarify the incidence, risk modifiers, natural history, and outcomes of thyroid dysfunction after IV ICM exposure in this population.
UR - https://www.scopus.com/pages/publications/105037857983
U2 - 10.1542/peds.2026-076640
DO - 10.1542/peds.2026-076640
M3 - Article
C2 - 42036119
AN - SCOPUS:105037857983
SN - 0031-4005
VL - 157
JO - Pediatrics
JF - Pediatrics
IS - 5
M1 - e2026076640
ER -